Inhaled liposomal ciprofloxacin protects against lethal tularemia in the common marmoset
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01232-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Rachel E Ireland und 8 weiteren Autor:innen. Beteiligte Einrichtung: CBR Division, Defence Science and Technology Laboratory (Dstl), Salisbury, Wiltshire, United Kingdom. Hauptthemen laut MEDLINE: Ciprofloxacin, Tularemia, Anti-Bacterial Agents, Francisella tularensis. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Defense Threat Reduction Agency.
Abstract (Originalsprache)
Francisella tularensis is a gram-negative, intracellular bacterium that causes the disease tularemia. Tularemia is prevalent in North America, Europe, and Asia and is typically treated with injected and orally administered antibiotics, including streptomycin, gentamicin, doxycycline, and ciprofloxacin, administered for 10 to 21 days. New therapeutic options are required to reduce the potential of a relapse of disease. Inhaled liposomal-encapsulated ciprofloxacin has demonstrated protection in a murine model of tularemia. The efficacy was further assessed in a nonhuman primate model of tularemia. Mixed-sex common marmosets were challenged with F. tularensis by the inhalational route, and the efficacy of ciprofloxacin delivered by either the inhalational (Apulmiq liposomal formulation) or oral route was compared. Antibiotics were initiated either at 24 h post-challenge (post-exposure prophylaxis) or at the onset of fever (treatment) and continued for 7 days. All control (untreated) animals succumbed to infection by 8 days post-challenge. All animals that received antibiotics, by either route, survived the duration of the study, with bacterial clearance in all but one animal that received inhalational ciprofloxacin. Antibiotic treatment also reduced the physiological and immunological responses observed when compared to animals that received no antibiotics. Histological changes in the lungs were less frequent, although mild, resolving lesions were present in animals treated with ciprofloxacin delivered at the onset of fever by either route.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CBR Division, Defence Science and Technology Laboratory (Dstl), Salisbury, Wiltshire, United Kingdom.
- Animal and Plant Health Agency, Addlestone, Surrey, United Kingdom.
- Aradigm Corporation, Hayward, California, USA.
ORCID-Profile: Rachel E Ireland, Sarah V Harding, Michelle Nelson
Förderung
- Defense Threat Reduction Agency
Zitieren
APA
Ireland, R. E., Nunez, A., Butcher, W., Davies, C., Blanchard, J. D., Dayton, F., Gonda, I., Harding, S. V., & Nelson, M. (2026). Inhaled liposomal ciprofloxacin protects against lethal tularemia in the common marmoset. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01232-25
Vancouver
Ireland RE, Nunez A, Butcher W, Davies C, Blanchard JD, Dayton F, et al. Inhaled liposomal ciprofloxacin protects against lethal tularemia in the common marmoset. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01232-25
BibTeX
@article{Ireland2026,
author = {Ireland, Rachel E and Nunez, Alejandro and Butcher, Wendy and Davies, Carwyn and Blanchard, James D and Dayton, Francis and Gonda, Igor and Harding, Sarah V and Nelson, Michelle},
title = {Inhaled liposomal ciprofloxacin protects against lethal tularemia in the common marmoset},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01232-25}
}
EUVIMED